PRME
Prime Medicine Inc

2,653
Mkt Cap
$691.51M
Volume
1.65M
52W High
$6.94
52W Low
$1.11
PE Ratio
-2.79
PRME Fundamentals
Price
$3.72
Prev Close
$3.83
Open
$3.94
50D MA
$3.85
Beta
2.16
Avg. Volume
2.93M
EPS (Annual)
-$1.35
P/B
5.72
Rev/Employee
$31,726.03
$454.94
Loading...
Loading...
News
all
press releases
Prime Medicine (NASDAQ:PRME) Shares Gap Up - Here's Why
Prime Medicine (NASDAQ:PRME) Shares Gap Up - What's Next...
MarketBeat·3h ago
News Placeholder
More News
News Placeholder
Prime Medicine (NYSE:PRME) Shares Gap Up - Should You Buy?
Prime Medicine (NYSE:PRME) Shares Gap Up - Should You Buy...
MarketBeat·3h ago
News Placeholder
Prime Medicine (NYSE:PRME) Earns Outperform Rating from Analysts at Oppenheimer
Oppenheimer assumed coverage on Prime Medicine in a research note on Thursday. They set an "outperform" rating and a $11.00 price objective on the stock...
MarketBeat·5h ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Trading Down 6.3% - Here's What Happened
Prime Medicine (NASDAQ:PRME) Shares Down 6.3% - Here's What Happened...
MarketBeat·24h ago
News Placeholder
Prime Medicine (NYSE:PRME) Shares Down 6.9% - Here's What Happened
Prime Medicine (NYSE:PRME) Trading Down 6.9% - Here's Why...
MarketBeat·24h ago
News Placeholder
HC Wainwright Predicts Stronger Earnings for Prime Medicine
Prime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for Prime Medicine in a research report issued on Wednesday, March 4th. HC...
MarketBeat·6d ago
News Placeholder
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Moderate Buy" from Analysts
Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports...
MarketBeat·6d ago
News Placeholder
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC
ARK Investment Management LLC increased its holdings in shares of Prime Medicine, Inc. (NYSE:PRME - Free Report) by 135.8% in the third quarter, according to the company in its most recent filing...
MarketBeat·7d ago
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
HighTower Advisors LLC Buys 312,401 Shares of Prime Medicine, Inc. $PRME
HighTower Advisors LLC raised its stake in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 1,463.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·11d ago
<
1
2
...
>

Latest PRME News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.